GFM
APGE icon

GF Fund Management’s Apogee Therapeutics APGE Stock Holding History

GF Fund Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154K Sell
1,163
-69
-6% -$6.22K ﹤0.01% 296
2026
Q1 		$104K Buy
1,232
+155
+14% +$11.3K ﹤0.01% 336
2025
Q4 		$81.3K Buy
1,077
+85
+9% +$5.35K ﹤0.01% 363
2025
Q3 		$39.4K Sell
992
-161
-14% -$6.15K ﹤0.01% 419
2025
Q2 		$50.1K Hold
1,153
– – ﹤0.01% 414
2025
Q1 		$43.1K Buy
1,153
+208
+22% +$8.04K ﹤0.01% 434
2024
Q4 		$42.8K Buy
+945
New +$48.2K ﹤0.01% 402

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

GF Fund Management's APGE Position: Q2 2026 in Review

GF Fund Management reduced its Apogee Therapeutics (APGE) stake by 5.6% in Q2 2026, selling an estimated $6.22K and leaving 1,163 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #296.

GF Fund Management first reported a position in APGE in Q4 2024 and has held it in 7 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • GF Fund Management held 1,163 shares of Apogee Therapeutics worth $154K as of Q2 2026.
  • GF Fund Management sold 69 Apogee Therapeutics shares in Q2 2026, an estimated $6.22K.
  • Apogee Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #296 holding.
  • GF Fund Management first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.